Literature DB >> 25136943

Surgery of primary lung cancer with oligometastatic m1b synchronous single brain metastasis: analysis of 37 cases.

Danjouma Housmanou Cheufou1, Stefan Welter1, Eleftherios Chalvatzoulis1, Daniel Christof2, Dirk Theegarten3, Georgios Stamatis1.   

Abstract

BACKGROUND: At the time of diagnosis, lung cancer has often metastasized already. Brain metastases, however, are associated with a poor prognosis (median survival of less than 1 year). We evaluated the changes of the median survival after resection of the cerebral metastases and primary non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: Between January 1999 and December 2009, 37 patients (22 men, 15 women; median age: 55.64 years; age range: 38-72 years) underwent surgery for primary NSCLC after craniotomy and removal of the synchronous single brain metastasis. The overall survival was evaluated and risk factors identified.
RESULTS: Mediastinal lymph node involvement was excluded with mediastinoscopy in 26 of the 37 patients. Postoperative N-stage was N0, N1, and N2 in 16 (43%), 10 (27%), and 11 (30%) patients, respectively. Histology was squamous cell carcinoma in 10 (27%), adenocarcinoma in 20 (54%), and large cell carcinoma in 7 (19%). The employed type of resection was anatomical segmentectomy in 6 and lobectomy in 31 patients. The 30-day mortality was 0% and postoperative complications occurred in 12 patients only (32%). The overall 1 and 2 years survival were 62 and 24%, respectively. None of the factors age, sex, tumor histology, primary location of the tumor, type of resection, adjuvant chemotherapy, or nodal status affected survival in the univariate analysis.
CONCLUSIONS: The oncologic lung resection of NSCLC after the resection of a single brain metastasis can be implemented without an increased risk of complications or mortality. Despite the stage IV disease, the median survival appears encouraging. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2014        PMID: 25136943     DOI: 10.1055/s-0034-1377060

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  8 in total

Review 1.  The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-Small Cell Lung Cancer.

Authors:  Elizabeth A David; James M Clark; David T Cooke; Joy Melnikow; Karen Kelly; Robert J Canter
Journal:  J Thorac Oncol       Date:  2017-08-24       Impact factor: 15.609

2.  Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer.

Authors:  James E Bates; Michael T Milano
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

3.  Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis.

Authors:  Shangbiao Li; Rui Zhu; Dianhe Li; Na Li; Xiaoxia Zhu
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 4.  The biology and treatment of oligometastatic cancer.

Authors:  Diane K Reyes; Kenneth J Pienta
Journal:  Oncotarget       Date:  2015-04-20

5.  Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy.

Authors:  Hao Bai; Jianlin Xu; Haitang Yang; Bo Jin; Yuqing Lou; Dan Wu; Baohui Han
Journal:  Onco Targets Ther       Date:  2016-07-11       Impact factor: 4.147

Review 6.  Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: a systematic review.

Authors:  Luca Bertolaccini; Monica Casiraghi; Giulia Sedda; Filippo de Marinis; Lorenzo Spaggiari
Journal:  Transl Lung Cancer Res       Date:  2021-07

7.  Lobectomy Can Improve the Survival of Patients With Non-small Cell Lung Cancer With Lung Oligometastatic.

Authors:  Lingwei Wang; Fanglei Jiao; Lin Dong; Qinchuan Li; Gang Liu; Xuefei Hu
Journal:  Front Surg       Date:  2021-07-05

8.  Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer Patients.

Authors:  Hong Shen; Ying Cao; Xiaofen Li; Yinuo Tan; Jiaqi Chen; Ziru Yang; Yiyao Kong; Ying Yuan
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.